晚期乳腺癌中的CDK4/6抑制剂，未来何去何从？
CDK4/6 inhibitors in advanced breast cancer, what is beyond?
作者信息
Mohammed Amrallah A, Rashied Hanaa, Elsayed Fifi Mostafa
机构信息
Medical Oncology Department, Faculty of Medicine, Zagazig University, Egypt.
King Salman Armed Forces Hospital, Tabuk City, KSA.
出版信息
Oncol Rev. 2019 Jul 29;13(2):416. doi: 10.4081/oncol.2019.416. eCollection 2019 Jul 22.
Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.
激素治疗耐药被认为是晚期乳腺癌（ABC）管理中的主要临床挑战。CDK4/6抑制剂（CDK4/6I）的使用可能会改变治疗格局。在这项授权综述中，我们将重点关注CDK4/6I在HR+/HER2-ABC管理中的适用作用、耐药机制以及未来有前景的应用。
Zotero 插件